Prostate cancer biomarkers: Are we hitting the mark?

Siegel, 2016, Cancer statistics, CA Cancer J Clin, 66, 7, 10.3322/caac.21332 Rosser, 2005, Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?, J Urol, 174, 1154, 10.1097/01.ju.0000169211.49050.8f Karnes, 2013, Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population, J Urol, 190, 2047, 10.1016/j.juro.2013.06.017 Cooperberg, 2010, Time trends and local variation in primary treatment of localized prostate cancer, J Clin Oncol, 28, 1117, 10.1200/JCO.2009.26.0133 Bolton, 2015, Predictors of prostate cancer specific mortality after radical prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy Registry, BJU Int, 116, 66, 10.1111/bju.13112 Fossati, 2015, Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric European prospective study, Eur Urol, 68, 132, 10.1016/j.eururo.2014.07.034 Catalona, 2011, A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range, J Urol, 185, 1650, 10.1016/j.juro.2010.12.032 Parekh, 2015, A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer, Eur Urol, 68, 464, 10.1016/j.eururo.2014.10.021 Konety, 2015, The 4Kscore(R) test reduces prostate biopsy rates in community and academic urology practices, Rev Urol, 17, 231 Stattin, 2015, Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study, Eur Urol, 68, 207, 10.1016/j.eururo.2015.01.009 Yang, 2016, PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer, Chin J Cancer Res, 28, 65 Marks, 2007, PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy, Urology, 69, 532, 10.1016/j.urology.2006.12.014 Tinzl, 2004, DD3(PCA3) RNA analysis in urine – a new perspective for detecting prostate cancer, Eur Urol, 46, 182, 10.1016/j.eururo.2004.06.004 Leyten, 2014, Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer, Eur Urol, 65, 534, 10.1016/j.eururo.2012.11.014 Merola, 2015, PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience, J Exp Clin Cancer Res, 34, 15, 10.1186/s13046-015-0127-8 Crawford, 2012, Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases, J Urol, 188, 1726, 10.1016/j.juro.2012.07.023 Perner, 2007, TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion, Am J Surg Pathol, 31, 882, 10.1097/01.pas.0000213424.38503.aa Hessels, 2007, Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer, Clin Cancer Res, 13, 5103, 10.1158/1078-0432.CCR-07-0700 Sanguedolce, 2016, Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: literature review, Clin Genitourin Cancer, 14, 117, 10.1016/j.clgc.2015.12.001 Salami, 2013, Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer, Urol Oncol, 31, 566, 10.1016/j.urolonc.2011.04.001 McKiernan, 2016, A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy, JAMA Oncol, 2882 Prensner, 2013, The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex, Nat Genet, 45, 1392, 10.1038/ng.2771 Prensner, 2014, RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1, Lancet Oncol, 15, 1469, 10.1016/S1470-2045(14)71113-1 Leyten, 2015, Identification of a candidate gene panel for the early diagnosis of prostate cancer, Clin Cancer Res, 21, 3061, 10.1158/1078-0432.CCR-14-3334 Van Neste, 2016, Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score, Eur Urol, 10.1016/j.eururo.2016.04.012 Wojno, 2014, Reduced rate of repeated prostate biopsies observed in ConfirmMDx clinical utility field study, Am Health Drug Benefits, 7, 129 Partin, 2014, Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies, J Urol, 192, 1081, 10.1016/j.juro.2014.04.013 Van Neste, 2016, Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies, Prostate, 10.1002/pros.23191 Knezevic, 2013, Analytical validation of the oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies, BMC Genomics, 14, 690, 10.1186/1471-2164-14-690 Leapman, 2016, Clinical utility of biomarkers in localized prostate cancer, Curr Oncol Rep, 18, 30, 10.1007/s11912-016-0513-1 Klein, 2014, A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling, Eur Urol, 66, 550, 10.1016/j.eururo.2014.05.004 Szulkin, 2015, Prediction of individual genetic risk to prostate cancer using a polygenic score, Prostate, 75, 1467, 10.1002/pros.23037 Cuzick, 2012, Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort, Br J Cancer, 106, 1095, 10.1038/bjc.2012.39 Cuzick, 2015, Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort, Br J Cancer, 113, 382, 10.1038/bjc.2015.223 Bishoff, 2014, Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy, J Urol, 192, 409, 10.1016/j.juro.2014.02.003 Klein, 2016, Decipher genomic classifier measured on prostate biopsy predicts metastasis risk, Urology, 90, 148, 10.1016/j.urology.2016.01.012 Zhao, 2016, The landscape of prognostic outlier genes in high-risk prostate cancer, Clin Cancer Res, 22, 1777, 10.1158/1078-0432.CCR-15-1250 Ross, 2016, Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer, Prostate Cancer Prostatic Dis, 19, 1, 10.1038/pcan.2015.31 Melling, 2016, Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer, Prostate, 76, 259, 10.1002/pros.23120 Al-Kafaji, 2016, Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: a potential novel non-invasive biomarker, Oncol Lett, 11, 1201, 10.3892/ol.2015.4014 Roberts, 2016, Prostate-based biofluids for the detection of prostate cancer: a comparative study of the diagnostic performance of cell-sourced RNA biomarkers, Prostate Int, 4, 97, 10.1016/j.prnil.2016.04.002 Salido-Guadarrama, 2016, Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone, Mol Med Rep, 13, 4549, 10.3892/mmr.2016.5095 Perera, 2016, Management of men with previous negative prostate biopsy, Curr Opin Urol, 26, 481, 10.1097/MOU.0000000000000315 Perera, 2016, An update on focal therapy for prostate cancer, Nature Rev Urol, 10.1038/nrurol.2016.177 Weerakoon, 2015, The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry, BJU Int, 115, 50, 10.1111/bju.13049